Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes
Heterologous Covid-19 Booster Vaccinations | NEJM
Sano y salvo on X: "Declaración conjunta de la @EMA_News y el @ECDC_EU sobre la posibilidad de usar dos vacunas #COVID19 diferentes, tanto para las dos primeras dosis como para la tercera
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant | Signal Transduction and Targeted Therapy
Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines: Expert Review of Vaccines: Vol 22, No 1
A 'mix and match' approach to SARS-CoV-2 vaccination | Nature Medicine
Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
What is a heterologous booster vaccine? | The Hindu - YouTube
Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people - The Lancet Infectious Diseases
Covid-19 vaccine mixing: could heterologous boosters improve immunity?
Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
Strategies and safety considerations of booster vaccination in COVID-19 | Biomolecules and Biomedicine
What is a heterologous booster COVID vaccine, and why should you take this jab?, ET HealthWorld
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination | Nature Medicine
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination | NEJM
COVID-19: safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine (Sputnik V)
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study - The Lancet Respiratory Medicine
Explained | What is a heterologous booster vaccine, and what are its advantages? - The Hindu
Homologous and Heterologous Covid-19 Booster Vaccinations | NEJM
